Normal view MARC view ISBD view

Resistance to Ibritumomab in Lymphoma edited by Makoto Hosono, Jean-François Chatal. - 1 recurso en línea (XIII, 158 páginas 18 ilustraciones,14 ilustraciones a color) - Resistance to Targeted Anti-Cancer Therapeutics 18 2196-5501 Biomedical and Life Sciences (Springer-11642) .

Clinical Use and Efficacy of Ibritumomab in B-cell Lymphoma -- Biology and Pathology of B-cell lymphoma -- Resistance to Y-90 Ibritumomab Tiuxetan Therapy -- Features of Ibritumomab as Radionuclide Therapy -- Radiological Evaluation of Response and Resistance of Ibritumomab -- Characteristics of Ibritumomab as Radionuclide Therapy Agent -- Resistance and Heterogeneity of Intratumoral Antibody Distribution -- Radiation Dosimetry in Ibritumomab Therapy -- Combining RAIT and immune-based therapies to overcome resistance in cancer? -- Prospects for enhancing efficacy of radioimmunotherapy -- Index.

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

ISBN: 9783319782386

Standard No.: 10.1007/978-3-319-78238-6 doi

Subjects--Topical Terms:
Cáncer

LC Class. No.: RC261 / 2018 EB